Cannabidiol/Palmitoylethanolamide

N/A

Report date: 2025/04/25 15:08:16

Base Information

Drug NameCannabidiol/Palmitoylethanolamide
Drug Alias NameRESPECTRUMCBD/PEASCI–210THX-210
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCannabinoid CB1 receptor antagonistsCannabinoid receptor agonistsPeroxisome proliferator-activated receptor α agonists +[4] 
TargetsCannabinoid CB1 receptorPeroxisome proliferator-activated receptor αCannabinoid CB2 receptor
Therapy Area/IndicationsAutism Spectrum DisorderDiabetic Neuropathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIsrael
CombinationsYes CannabidiolPalmitoylethanolamide
Global Highest StatusClinical
Highest Status in ChinaN/A
Originator CompaniesTherapix Biosciences Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSciSparc Ltd
Inactive CompaniesPure Green Pharmaceuticals Inc
Active IndicationsAutism Spectrum Disorder
Inactive IndicationsDiabetic Neuropathies

Other Information

ATC CodeN/A
Related LinksN/A